NCT00003125View on ClinicalTrials.gov

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 1998

Primary Completion Date

November 30, 2004

Study Completion Date

November 30, 2004

Conditions
Breast CancerEsophageal CancerGastric CancerLung CancerPancreatic CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

ALVAC-CEA vaccine

BIOLOGICAL

aldesleukin

BIOLOGICAL

sargramostim

BIOLOGICAL

vaccinia-CEA vaccine

Trial Locations (2)

20007

Lombardi Cancer Center, Georgetown University, Washington D.C.

20889-5000

National Naval Medical Center, Bethesda

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Georgetown University

OTHER

NCT00003125 - Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors | Biotech Hunter | Biotech Hunter